COSON Co., Ltd. Overview
Yuhan Cosmetics, formerly COSON, is a small South Korean cosmetics OEM/ODM manufacturer that is being rebuilt by its controlling shareholder, Yuhan Corporation, one of Korea's largest pharmaceutical companies. Between 2014 and 2019, COSON grew from a reverse-listed DVR maker into a top-tier colour-cosmetics contract manufacturer, peaking at roughly KRW 109 bn of revenue in FY2019. Its growth came from co-developing YG Entertainment's Moonshot brand (including the "GD Cushion"), private-label supply to MINISO through a Guangzhou subsidiary, and China-facing distribution. The 2017 THAAD retaliation, failed brand ventures, COVID-19, three consecutive audit disclaimers (FY2020–FY2022), court rehabilitation (2022–2023) and KOSDAQ delisting (October 2023) collapsed the business. FY2025 revenue was about KRW 1.9 bn against an operating loss of KRW 5.8 bn. Equity was negative KRW 27.8 bn at end-Q1 2026. The investment case now rests on Yuhan's continued funding and on whether the "Trusted Science, Beautiful Solutions" pharma-linked ODM repositioning can win new customers.
What the company does
Yuhan Cosmetics develops and manufactures cosmetic products under contract for brand owners (OEM: manufacturing to the customer's formula; ODM: the manufacturer develops and proposes the formula). Historically the product scope covered both skin care and colour cosmetics. Simply Wall St's description lists skin-care formats (solubilised products, masks, cleansing, emulsions, sun care) and make-up formats (emulsion-based, lip and powder products). Trade databases also record BB and CC creams.
Company's own description (paraphrased)
At the October 2025 renaming, the company set out a vision of "Trusted Science, Beautiful Solutions." It says it will combine Yuhan Corporation's accumulated scientific research know-how with cosmetics development, offering an end-to-end service from product planning through R&D, production and quality control. It named three core values: Innovation First, Trusted Partnership and Sustainable Growth. It also named excellence, scientific approach and partnership as guiding principles, and committed to continued R&D investment (Herald Economy; Hankyung, Oct 2025).
Independent characterisation
On the evidence, the company today is a sub-scale, loss-making contract manufacturer in turnaround. Revenue in FY2025 (KRW 1.9 bn) was about 1.7% of its FY2019 peak (KRW 109.3 bn). Quarterly revenue in 2026 has run at about KRW 0.4 bn, while quarterly operating losses have been KRW 0.9–1.4 bn (Dailypharm, Jul 2026). Its balance sheet is fully impaired (equity of negative KRW 27.8 bn at end-Q1 2026). The business continues because Yuhan Corporation keeps injecting equity: KRW 105 bn... correction, KRW 10.5 bn across three issues in 2025, and KRW 5.0 bn approved in July 2026.
The model has two strands:
-
B2B contract manufacturing (core). Revenue is per-unit manufacturing fees, with margins driven by plant utilisation.
-
Own-brand B2C (nascent). The subsidiary Yucostory sells the "The Yu" (더이유) brand on Naver Smart Store; Yuhan Cosmetics manufactures it (Mar 2026).
Revenue model mix
| Revenue stream | Share of revenue | Status |
|---|---|---|
| Product manufacturing (OEM/ODM) | Not publicly disclosed; historically the large majority | Core |
| Own brands (Moonshot co-venture historically; The Yu from 2026) | — | Nascent |
| Services / subscription / licensing | None disclosed | — |
Value-chain position and customers
The company sits in the mid-stream of the beauty value chain. It buys raw materials and packaging, formulates and fills, and supplies finished goods to brand owners, who handle marketing and retail. Named historical customers and partners include:
-
YG Entertainment's Moonshot brand (development and production);
-
MINISO private-label products and the Chinese colour brand "Wushenji" (우센지) via the Guangzhou subsidiary (2017);
-
Guangzhou Huanya Cosmetics (distribution partner, 2014);
-
apM Group (Dongdaemun) private-label and collaboration products (2016);
-
a US consignee, Astral Health and Beauty, which received shipments through June 2023 (Panjiva).
End-markets
Mass and masstige skin care and colour cosmetics, sold domestically through retail, duty-free and online channels, and exported through brand customers, historically with heavy exposure to China.
Strategy
Stated strategy (themes paraphrased)
-
Pharma-science-led ODM. Use Yuhan's research know-how and quality systems to differentiate in formulation, safety and QC (Oct 2025 renaming).
-
Full-service partner. Cover planning, R&D, production and QC, and focus on customers' brand goals.
-
Diversify into own brands. Launch "The Yu" through Yucostory (2026), with KRW 1.0 bn of the July 2026 raise earmarked for new brand development.
-
Capacity refresh. KRW 1.2 bn for an additional cell line and KRW 1.8 bn for filling, analysis and testing equipment (Jul 2026).
-
Comprehensive ODM/OEM ambition. At the April 2024 "second founding," management presented a medium- to long-term plan to become a comprehensive ODM/OEM company. Detailed targets were not disclosed.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail |
|---|---|---|
| Jan 2025 | Equity injection | KRW 3.0 bn rights issue to Yuhan |
| Sep 2025 | Equity injection | KRW 2.5 bn rights issue to Yuhan |
| Oct 2025 | Equity injection and rebrand | KRW 5.0 bn rights issue; renamed Yuhan Cosmetics; new vision and values |
| Q4 2025 | New subsidiary | Yucostory (100%, KRW 5 m capital) for B2C sales |
| Early 2026 | Own-brand launch | "The Yu" vita-exosome mist, cream and ampoule on Naver Store |
| Mar–Apr 2026 | Capital-structure event (third party) | Sungwoo Electronics' attempted KRW 15 bn sale of its BW, cancelled |
| Jul 2026 | RCPS funding | KRW 5.0 bn RCPS to Yuhan (4,545,454 shares; redemption window 28 Jul 2028 – 28 Jul 2031 at KRW 1,100 per share; conversion from 28 Jul 2027) |
ESG commitments and cost programmes
No quantified ESG commitments or cost-reduction targets are disclosed. "Sustainable Growth" is named as a core value without metrics.
Medium-term financial targets
None publicly disclosed. A management representative said in January 2024 that the goal of rehabilitation was to reduce debt and return to past revenue levels (Hitnews, paraphrased). No figures were attached.
Products & Services
The company has not published a current product catalogue in sources reviewed. The list below compiles products and formats named in filings, press and trade data. Pricing is not disclosed for any contract-manufactured item.
Contract manufacturing formats (OEM/ODM)
| Category | Formats | Target customer | Notes |
|---|---|---|---|
| Skin care | Solubilised products (toners, essences), masks, cleansing, emulsions (lotions, creams), sun care | Brand owners | Simply Wall St description |
| Base make-up | BB creams, CC creams, cushion foundations | Brand owners | EMIS; Moonshot products |
| Colour cosmetics | Lip products, powders, emulsion-based make-up | Brand owners | Osan plant made colour possible from March 2014 |
| Private label | Retailer own-brand cosmetics | MINISO (China), apM Group (Korea) | 2016–2017 |
Named flagship and brand-linked products
| Product / line | Brand owner | Year | Description |
|---|---|---|---|
| Micro Fit Cushion ("GD Cushion") | Moonshot (YG) | c.2015 | Cushion foundation named after G-Dragon; Time Out describes it as long-wearing and light-textured |
| Moonshot launch range (208 SKUs) | Moonshot (YG) | Oct 2014 | 21 skin care, 23 base make-up and 162 colour items, aimed at women aged 20–39 |
| Powder Duo (e.g., Minty Wind, Aries Scent) | Moonshot | 2,015 | Eye colour duo, S/S 2015 collection |
| Neutral Skin Illuminator SPF50 PA+++ | Moonshot | 2,015 | Tone-up base used in duty-free promotions |
| Colour Moonwalk Cream Paint | Moonshot | 2,015 | Cream colour product |
| Perfect Cleansing Water | Moonshot | 2,015 | Cleansing water |
| Lipstick line inspired by BLACKPINK (16 shades) | Moonshot | 2,018 | Matte and semi-matte shades |
| MINISO private-label cosmetics | MINISO | 2,017 | Supplied from Guangzhou subsidiary |
| Wushenji colour cosmetics | Wushenji (China) | 2,017 | Supplied from Guangzhou subsidiary |
Note: COSON's manufacturing role is documented for the Moonshot brand overall. Plant-level attribution of each individual Moonshot SKU is not disclosed.
Own brand (2026)
| Product | Brand | Channel | Manufacturer |
|---|---|---|---|
| Vita Exosome Capsule Mist | The Yu (더이유) | Naver Store via Yucostory | Yuhan Cosmetics |
| Vita Exosome Moisture Cream | The Yu | Naver Store via Yucostory | Yuhan Cosmetics |
| Vita Exosome Ampoule | The Yu | Naver Store via Yucostory | Yuhan Cosmetics |
Pricing, sales volumes and launch dates beyond "early 2026" are not publicly disclosed.
Financial Narrative
Disclosure caveats
-
FY2020, FY2021 and FY2022 financial statements received auditor disclaimers of opinion. Figures for those years are unaudited in substance and should be used with caution.
-
FY2023 received an unqualified ("appropriate") opinion (Jangup Shinmun, Apr 2024).
-
After delisting, only headline revenue and operating income (via Dailypharm and Cosinkorea, citing FSS filings) and an end-Q1 2026 balance-sheet summary are publicly reported. Gross profit, EBITDA, net income, EPS and cash flows are not available for most years.
Income statement (FY2021–FY2025)
Sources: Dailypharm (23 Jul 2026; 3 Sep 2025; 7 Apr 2023), citing FSS filings. Growth and margins computed. Cosinkorea (Apr 2026) gives the FY2024→FY2025 decline as 53.2% using unrounded figures. No dividends are recorded in any source reviewed; zero is shown on that basis.
Revenue CAGR FY2021–FY2025: about -50.5% per year (KRW 31.6 bn → 1.9 bn).
Aggregator data point (TTM to 30 Jun 2023, Simply Wall St): revenue KRW 10.5 bn; cost of revenue KRW 13.8 bn; gross profit -KRW 3.3 bn; other expenses KRW 19.3 bn; earnings -KRW 22.7 bn. This shows that even gross margin was negative during the rehabilitation period.
Long-run revenue and profit history (FY2013–FY2025)
Sources: FY2013 Cosinkorea (2018); FY2014–FY2017 Edaily and Etoday (Mar 2018); FY2015–FY2016 operating and net income Cosmorning (2017, consolidated); FY2019–FY2025 Dailypharm (2025–2026). FY2018 revenue exceeded KRW 100 bn (Dailypharm states three consecutive years above KRW 100 bn in FY2017–FY2019), but the exact figure was not found.
Source conflicts noted:
-
Etnews (Dec 2015) cites FY2015 standalone revenue of KRW 15.5 bn and operating income of KRW 1.5 bn, against KRW 61.9 bn consolidated. The two bases are not reconcilable from public data and may reflect a partial period.
-
FY2017 revenue appears as KRW 100.4 bn (Edaily) and KRW 100.5 bn (Cosinkorea).
-
Cosmorning (Apr 2018) lists COSON among companies whose FY2017 profit fell 76.5%, without specifying the exact metric in the excerpt reviewed. FY2017 operating income is therefore left blank.
Balance sheet
Latest disclosed position (end-Q1 FY2026, Dailypharm): total assets KRW 19.4 bn; total liabilities KRW 47.2 bn; total equity -KRW 27.8 bn (complete capital impairment). Liabilities were more than twice assets.
Historical capital structure (end-Q1 FY2019, DART via Findata): share capital KRW 11.1 bn (18,697,161 common and 3,511,632 preferred shares). The CEO had personally guaranteed bank borrowings from Woori, Kookmin, Hana, Shinhan and KDB totalling KRW 23.1 bn, plus about KRW 1.0 bn of performance guarantees via Seoul Guarantee Insurance (KRW 24.1 bn combined in that table).
Cash flow
Equity raised: Dailypharm. In FY2024 Sungwoo Electronics also subscribed KRW 10 bn of bonds with warrants (debt with equity option). No buybacks or dividends are recorded; zeros are shown on that basis.
Ratios
With negative equity (end-Q1 2026) and negative operating income in every year since FY2020, ROE, debt/equity, net debt/EBITDA and interest coverage are not meaningful even where inputs exist. The only computable leverage indicator is liabilities/assets of about 2.4x at end-Q1 2026 (47.2 / 19.4).
Commentary on trends, inflections and drivers
Growth phase (FY2013–FY2019). Revenue grew about tenfold, from KRW 10.6 bn (FY2013) to KRW 109.3 bn (FY2019). Three drivers stand out. First, the March 2014 start-up of the Osan plant added colour cosmetics capacity. Second, the YG/Moonshot partnership gave COSON visibility and volume. Third, the Guangzhou subsidiary won MINISO private-label business, which offset THAAD-related weakness in 2017. In this phase COSON was consistently profitable at the operating line (it posted no operating loss between FY2015 and FY2019, per Chosun Biz's statement that FY2020 was its first loss since 2014). FY2015–FY2016 operating margins were about 10–11%.
First inflection (FY2017). Sell-side forecasts (Hyundai Securities, Dec 2016) expected FY2017 operating income near KRW 19.9 bn on KRW 103.3 bn of revenue. Revenue arrived broadly on target, but profitability fell sharply (Cosmorning's 76.5% decline reference). This suggests brand-side costs and mix deterioration, with China exposure the critical swing factor after THAAD.
Collapse (FY2020–FY2022). Revenue fell 16% in FY2020 and then 66% in each of FY2021 and FY2022. Operating losses of KRW 14.7 bn and 15.0 bn in FY2020–FY2021 exceeded the best annual operating profit of the growth phase. Chosun Biz attributes the turn to anti-Korea sentiment in China and the rise of Chinese domestic brands. Press accounts also point to weak brand businesses. The audit disclaimers then cut off normal financing, and the company entered court rehabilitation in April 2022.
Post-rehabilitation (FY2023–H1 FY2026). Operating losses have narrowed in absolute terms (KRW 7.0 bn → 5.8 bn), but revenue has kept falling faster than costs. By Q2 2026 the quarterly operating loss was more than three times quarterly revenue. The company is not yet showing revenue stabilisation; cost reduction alone has not been enough to approach breakeven.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cosmetics manufacturing and sales revenue (KRW Bn) | 7.5 | 4.0 | 1.9 |
Cosmetics operating income (KRW Bn) | -7.0 | -5.9 | -5.8 |
Operating margin (%) | -93.3 | -147.5 | -305.3 |
Share of total revenue (%) | 100 | 100 | 100 |
Group Entities
| Entity | Ownership | Function | Status |
|---|---|---|---|
Yuhan Cosmetics Co., Ltd. (parent) | Yuhan Corp. largest holder | ODM/OEM manufacturing | Operating |
Yucostory (유코스토리) | 100% | Online sale of the "The Yu" brand | Founded Q4 2025 |
Guangzhou COSON (China) | — | Historical China plant (MINISO PB) | Current status not disclosed |
Hong Kong JV with Guangzhou Huanya (and YG participation) | — | China brand and distribution vehicle (2014) | Current status not disclosed |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 31.6 | 10.6 | 7.5 | 4.0 | 1.9 |
Revenue growth YoY (%) | -65.6 | -66.5 | -29.2 | -46.7 | -52.5 |
Operating income (KRW Bn) | -15.0 | -9.6 | -7.0 | -5.9 | -5.8 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | -47.5 | -90.6 | -93.3 | -147.5 | -305.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 10.6 | 26.4 | 61.9 | 83.1 | 100.4 | 109.3 | 91.9 | 31.6 | 10.6 | 7.5 | 4.0 | 1.9 |
Operating income (KRW Bn) | — | — | 6.9 | 8.1 | — | — | -14.7 | -15.0 | -9.6 | -7.0 | -5.9 | -5.8 |
Net income (KRW Bn) | — | — | 4.5 | 6.8 | — | — | — | — | — | — | — | — |
Revenue History
| Period | Revenue (KRW Bn) | Operating income (KRW Bn) | Net income (KRW Bn) | Source |
|---|---|---|---|---|
H1 FY2017 | 49.4 (+18.8% YoY) | 4.2 (+10.4%) | 3.0 (+13.2%) | Cosmorning, Aug 2017 |
Q1 FY2026 | 0.4 | -0.9 | — | Dailypharm, Jul 2026 |
Q2 FY2026 | 0.4 | -1.4 | — | Dailypharm, Jul 2026 |
“—” = not publicly disclosed.
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Equity raised from Yuhan Corp. (KRW Bn) | 0 | 0 | 0 | 5.0 | 10.5 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total (KRW Bn) | 7.5 | 4.0 | 1.9 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Trading halt | From March 2021 (audit disclaimer) to 10 October 2023 | Dealsite |
Liquidation trading | 11–19 October 2023 | Cosinkorea |
First-day liquidation move | -87.76% | Cosinkorea |
Week of liquidation start | -92.05% | Cosinkorea |
Last aggregator market capitalisation | KRW 4.4 bn | Simply Wall St (stale) |
Analyst Ratings & Targets
| Date | Broker | Rating | Key call |
|---|---|---|---|
20 Jun 2014 | Woori Investment & Securities | Target price KRW 7,750 | Described as the cosmetics name with the highest China growth potential; 3-year revenue and operating-income CAGR forecasts of 38.3% and 57.5% |
7 Apr 2016 | Daishin Securities | Buy | Q1 FY2016 standalone revenue forecast KRW 19.1 bn (+54% YoY) |
12 Apr 2016 | Hana Financial Investment | Not rated | Expected revenue and operating income growth above 50% YoY |
31 Oct 2016 | Hanyang Securities | Not rated | China acceleration |
1 Dec 2016 | Hyundai Securities | Buy | FY2017E revenue KRW 103.3 bn, operating income KRW 19.9 bn |
25 Aug 2017 | Golden Bridge Investment & Securities | Coverage dropped | — |
22 Nov 2017 | Taurus Investment & Securities | Buy | FY2018 earnings upturn expected |
Valuation Multiples
| Multiple | Yuhan Cosmetics | Peers |
|---|---|---|
P/E | Not applicable (unlisted; loss-making) | Not compiled |
EV/EBITDA | Not applicable | Not compiled |
EV/Sales | Not applicable | Not compiled |
P/B | Not applicable (negative equity) | Not compiled |
Capital Markets — Dividend history
| Item | Status |
|---|---|
Dividend history | No dividends recorded in sources reviewed |
Moody's / S&P / Fitch ratings | Not rated |
Debt maturity profile | Not disclosed. Known instruments: Sungwoo BW (KRW 10 bn, 2024; maturity not disclosed); Yuhan RCPS redeemable 28 Jul 2028 – 28 Jul 2031 |
Analyst Conclusions
Management guidance and consensus
There is no published financial guidance and no consensus forecast. Management's stated aims are qualitative: become a trusted, science-based ODM partner, build new brands, and return toward historical revenue levels.
Bull-case arguments
-
Strong, patient parent. Yuhan has shown willingness to fund repeatedly: five injections over 2024–2026 plus the July 2026 RCPS. Its record FY2025 earnings (operating income KRW 104.4 bn) make a few billion won a year affordable.
-
Market tailwind. Korean cosmetics exports hit records in 2025 (US$11.4 bn) and grew 27% in H1 2026. The 81-company ODM sector grew revenue 11.8%. Even a small share of indie-brand overflow would multiply the current KRW 1.9 bn revenue base.
-
Operating leverage. Fixed costs are already sunk in an existing CGMP plant. Each incremental contract drops through at high marginal contribution, so modest wins could narrow losses quickly.
Bear-case arguments
-
Revenue still falling. Revenue declined in each of the last six years and fell again in 2026 (KRW 0.4 bn per quarter), despite rebranding and new funding. Nothing in the data yet shows that customers are returning.
-
Balance sheet. Equity of -KRW 27.8 bn and liabilities of KRW 47.2 bn mean the business would be insolvent without parent support. Hybrid instruments (BW, RCPS) add future claims.
-
Structural competition. Cosmax and Kolmar earn 8–9% margins at about KRW 2.4–2.7 trillion revenue and offer global plants, deep R&D and proven reliability. Indie brands prioritise speed and minimum-order flexibility, where incumbents and many nimble small ODMs already compete.
Catalysts and monitorables (next 12 months)
| Item | Why it matters |
|---|---|
| Q3 and Q4 FY2026 revenue | Any quarter above KRW 1 bn would signal real customer wins |
| FY2026 audit opinion | Must remain unqualified |
| Deployment of July 2026 capex (cell line, filling, testing) | Indicates capacity readiness |
| Sell-through of "The Yu" | Test of B2C viability |
| Resolution of the Sungwoo BW / warrant overhang | Ownership clarity |
| Any captive contracts from Yuhan group businesses | Easiest route to base-load volume |
| Further Yuhan funding decisions | Signal of continued parent commitment |
| Conversion of RCPS (from July 2027) or redemption (from July 2028) | Capital-structure clarity |
Concluding analyst verdict
COSON's arc, from a reverse-listed DVR shell to Korea's fourth-ranked colour-cosmetics ODM and then to a delisted, capital-impaired micro-manufacturer, is a cautionary example of K-beauty's China-dependent boom. Between FY2013 and FY2019 the company showed genuine formulation skill and commercial agility. Revenue rose tenfold to about KRW 109 bn, supported by the Moonshot partnership and MINISO private-label supply. That growth rested on concentrated customers and China exposure. When THAAD retaliation, failed brand bets and COVID-19 arrived together, weak financial controls (three consecutive audit disclaimers) turned an operating downturn into a solvency and listing crisis.
The successor entity, Yuhan Cosmetics, is best analysed as a strategic option held by Yuhan Corporation rather than as a standalone investment. Its FY2025 revenue of KRW 1.9 bn and KRW 5.8 bn operating loss, along with negative equity of KRW 27.8 bn at end-Q1 2026, mean value depends almost entirely on the parent's continued willingness to fund and on the plant's ability to win new contracts. The external backdrop is the best it has been in a decade: record Korean exports, a growing ODM sector and indie brands that need outsourced capacity. Yet the company's revenue has kept falling through 2026 despite rebranding.
On balance, the evidence supports a high-risk, binary outlook. A credible turnaround requires visible quarterly revenue growth in H2 2026 and FY2027, a sustained clean audit, and ideally captive or anchor volume from Yuhan group businesses. Absent these signs within the next 12–18 months, the more probable outcomes are further dilutive recapitalisation by Yuhan, an eventual merger into a Yuhan affiliate, or a sale of the Osan asset. For external stakeholders such as customers, suppliers and creditors, exposure should be underwritten against Yuhan's support, not against Yuhan Cosmetics' own balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Lee Jong-ho (이종호) | Co-CEO | By Oct 2025; start date not disclosed | — |
Cho Il-hyun (조일현) | Co-CEO | By Oct 2025; start date not disclosed | — |
Kim Jae-yong (김재용) | Non-executive director | By 2024 | Head of Planning & Finance, Yuhan Corporation |
Kim Dong-geun (김동근) | Statutory auditor | By 2024 | Commercialisation Strategy team leader, Yuhan Corporation |
Lee Dong-geon (이동건) | CEO; also court-appointed custodian during rehabilitation | Nov 2012 – at least May 2023 (term to Nov 2024) | Born Jan 1968; B.S. and M.S. Chemical Engineering, Yonsei University; senior researcher at Pacific (Amorepacific) R&D; former CEO of Navion and Mizon. Held 2,504,907 shares (Q1 FY2023) |
Byun Jae-han (변재한) | Head of Finance & Accounting (non-registered) | About 13 years to 2023 | Former accounting team head at Daea Lead Wire and at 3H |
Han Sang-ho (한상호) | CEO of 3H | Nov 2007 – Nov 2012 | — |
Kim Dong-yeon (김동연) | CEO of Picaso Info & Comm | to Nov 2007 | — |
Kim Hee-sun (김희선) | Marketing executive (Managing Director) | c.2015 | Ran the Trend Lab initiative |
Choi Young-wook (최영욱) | Inside director (cross-appointed) | 2,020 | CEO of Audin Futures |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Yuhan Corporation | 25.43% of common; 21.69% of preferred | End-Q1 2026 | Dailypharm, Jul 2026 |
Yuhan Corporation | 32.5% (common basis) | End-2025 | Press via Nate, Mar 2026 |
Yuhan Corporation | 32.5% (11.73 m shares) | Apr 2024 | Jangup Shinmun |
Sungwoo Electronics (KOSDAQ: 081580) | Warrants over 9,090,909 shares (25.18% of total, as reported) | Jul 2024 | Dailypharm, Jul 2024 |
Cruise Holdings (크루즈홀딩스) | Allotted one-third of the first Jan 2024 issue (2 m shares implied) | Jan 2024 | Hitnews |
Baytree (베이트리) | 15.3% (20,980,102 shares), briefly largest | Sep 2023 | Dailypharm, Nov 2023 |
Lee Dong-geon (former CEO) | 11.28% | Q1 2019 | Findata (DART) |
Governance Overview
| Metric | FY2015 | FY2018 | FY2019 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Yuhan stake (%) | 3.88 | 12.3 | 12.18 | 11.4 | 32.5 |
Competitive Landscape
Key Competitors
| Competitor | Listing | FY2025 revenue (KRW Bn) | FY2025 operating income (KRW Bn) | Positioning vs. Yuhan Cosmetics | Source |
|---|---|---|---|---|---|
Kolmar Korea | KOSPI | 2722.4 (consolidated) | 239.6 | Largest by revenue; skin care, sun care, pharma via HK inno.N | Herald Economy, Feb 2026 |
Cosmax | KOSPI | 2,398.8 | 195.8 | World's largest pure-play cosmetics ODM; strong colour; China, US, SE Asia plants | Sidae, Feb 2026 |
Cosmecca Korea | KOSDAQ | — | 83.5 | Third of Korea's "big three" ODMs; US subsidiary Englewood Lab | Cosinkorea, Apr 2026 |
Englewood Lab | KOSDAQ | — | 37.4 | US-based ODM controlled by Cosmecca | Cosinkorea, Apr 2026 |
Korea Cosmetics Manufacturing | KOSPI | — | 32.9 | Domestic ODM | Cosinkorea, Apr 2026 |
Intercos Korea | Unlisted (Intercos group) | — | — | Colour-cosmetics ODM, also in Osan (Gajang industrial complex) | Cosmorning |
Cosvision | Unlisted | — | — | Mid-tier ODM (FY2017 revenue KRW 185.8 bn) | Cosinkorea, 2018 |
C&F (씨엔에프) | Unlisted | — | — | Mid-tier ODM (FY2017 revenue KRW 147.2 bn) | Cosinkorea, 2018 |
CTK Cosmetics | KOSDAQ | — | — | Colour-cosmetics ODM | CNC News |
Yuhan Cosmetics (subject) | Unlisted | 1.9 | -5.8 | Micro-scale; turnaround | Dailypharm |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Yuhan Cosmetics | Kolmar Korea | Cosmax | Cosmecca Korea |
|---|---|---|---|---|
Revenue (KRW Bn) | 1.9 | 2,722.4 | 2,398.8 | — |
Revenue growth YoY (%) | -52.5 | — | 10.7 | — |
Operating income (KRW Bn) | -5.8 | 239.6 | 195.8 | 83.5 |
Operating margin (%) | -305.3 | 8.8 | 8.2 | not computable |
“—” = not publicly disclosed.
Recent Developments
The table records every development found in the window, followed by earlier context that remains relevant.
Leadership changes, guidance revisions, litigation, layoffs and hiring:* none publicly reported in the 18-month window beyond the co-CEO arrangement disclosed at the renaming.



